NCT00563992View on ClinicalTrials.gov

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Bipolar Disorder
Interventions
DRUG

Lithium

Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.

DRUG

Valproic acid

Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.

Trial Locations (1)

10032

New York State Psychiatric Institute/Columbia University, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT00563992 - Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder | Biotech Hunter | Biotech Hunter